Mitochondrial transcription factor A contributes to cisplatin resistance in patients with estrogen receptor-positive breast cancer

The results of the present study provided evidence that resistance to cisplatin chemotherapy in estrogen receptor ‐positive breast cancer may be through TFAM and indicated that TFAM may be a target for chemoresistance in patients with breast cancer

Wei Gao; Mei-Hong Wu; Ning Wang; Ming-Zheng Ying; Ying-Yi Zhang; Jing Hua; Liu Chuan; Ya-Jie Wang

2016

Scholarcy highlights

  • Breast cancer is the most common type of cancer diagnosed among women and, in America, one in eight women develop breast cancer in their lifetime, with breast cancer accounting for almost one in eight cases of cancer and being the second leading cause of cancer‐associated mortality among women
  • The present study further investigated whether TFAM regulates the sensitivity of estrogen receptor‐positive breast cancer cell to cisplatin
  • It was found that TFAM promoted ER‐positive breast cancer cell survival following cisplatin treatment
  • It has been shown that patients with ER‐positive breast cancer are more likely to exhibit the features of cisplatin resistance
  • Regarding the sensitivity of breast cancer cells to cisplatin, the findings of the present study were consistent with previous evidence showing that ER‐negative breast cancer cells are more sensitive to cisplatin treatment, and ER‐positive breast cancer cells are more tolerant to cisplatin
  • It is known that several oncogenic genes and tumor suppressors are associated with cisplatin sensitivity, including AKT, c‐myc and p53 ; cisplatin resistance is a cell type‐ and tissue dependent‐phenomenon, and the clinical mechanisms leading to cisplatin resistance are complex
  • It was found that TFAM promoted estrogen receptor‐positive breast cancer cell survival following cisplatin treatment

Need more features? Save interactive summary cards to your Scholarcy Library.